HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Dipyridamole

HCID 3108
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
58-32-2
Standard SMILES
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
InChIKey
IZEKFCXSFNUWAM-UHFFFAOYSA-N
Molecular formula
C24H40N8O4
Average molar mass
504.6 g/mol
Monoisotopic mass
504.31725179

Overview

Dipyridamole is a pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. It has a role as a vasodilator agent, a platelet aggregation inhibitor, an adenosine phosphodiesterase inhibitor and an EC 3.5.4.4 (adenosine deaminase) inhibitor. It is a member of piperidines, a tetrol, a pyrimidopyrimidine and a tertiary amino compound.

Names & identifiers

Preferred name
Dipyridamole
IUPAC
2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
English name
Dipyridamole
Molecular formula
C24H40N8O4
Molecular weight
504.63

Names & synonyms

dipyridamole58-32-2PersantinDipyridaminePersantineCurantylDipyudamineDipiridamolCleridium 150DypyridamolIv PersantineDipyridamolum
Show more names
DIPYRIDAMOLdypyridamoleAnginalDipyrdamoleDipyridamole (200 mg)ra8RA 8
DipyramidoleNSC-515776DTXSID604066864ALC7F90C2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanolB01AC07NSC5157762-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)pyrimido[5,4-d][1,3]diazin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol

Database identifiers

CAS
58-32-2
PubChem CID
3108
DTXSID
DTXSID6040668
ChEMBL
CHEMBL932
ChEBI
CHEBI:4653
UNII
64ALC7F90C
EC Number
200-374-7
Nikkaji
J8.585E

Properties

Computed structural properties

XLogP
0.7
Topological polar surface area
145 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
12
Rotatable bonds
12
Heavy atoms
36
Formal charge
0
Complexity
561

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 items

1.5

2.17

Solubility · 3 items

Slightly

9.22e-01 g/L

10.7 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 items

Breastfeeding; Lactation; Milk, Human; Phosphodiesterase Inhibitors; Vasodilator Agents; Platelet Aggregation Inhibitors

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point163 °C
Physical DescriptionSolid
Collision Cross Section · 3 items

223.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

227.5 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

217.55 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H315 (98.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Other Safety InformationIMAP assessments - Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (98.7%)

Toxicology

Hepatotoxicity · 1 item

Dipyridamole has been associated with a low rate of serum enzyme elevations during therapy, but in large clinical trials the frequency of liver enzyme abnormalities was similar with dipyridamole therapy as with placebo. Cases of clinically apparent acute liver injury from dipyridamole have not been published although hepatitis is listed as a potential side effect in the product label. The clinical features of the liver injury linked to dipyridamole have not been described.

Adverse EffectsThe most frequently reported adverse effects include:
Toxicity SummarySigns and Symptoms of Overdose
Drug Induced Liver Injury

Chemistry & industry

Pharmacology

ATC Code · 2 items

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein Binding99%
Pharmacodynamics · 1 item

Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.

Mechanism of Action · 1 item

Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.

Biological Half-Life40 minutes
Metabolism/Metaboliteshepatic
FDA Pharmacological Classification · 6 items

64ALC7F90C

DIPYRIDAMOLE

Physiologic Effects [PE] - Decreased Platelet Aggregation

Established Pharmacologic Class [EPC] - Platelet Aggregation Inhibitor

Dipyridamole is a Platelet Aggregation Inhibitor. The physiologic effect of dipyridamole is by means of Decreased Platelet Aggregation.

DIPYRIDAMOLE

MeSH Pharmacological Classification · 3 items

Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Related reactions

1 records
New reaction record
HRID 1885712 reaction equation
HRID 1885712As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Physicochemical properties

Melting point
165 · 165-166 °C (lit.)
Boiling point
593.96 °C · 593.96°C (rough estimate)
Density
1.2046 · 1.2046 (rough estimate)
refractive index
1.691 · 1.6910 (estimate)
storage temp.
room temp
solubility
DMSO: soluble
form
powder
pka
6.4 · pKa 6.4 (Uncertain)
color
yellow
Water Solubility
Soluble in chloroform, methanol, dilute acids, ethanol. Slightly soluble in water.
Merck
14 · 14,3346
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
InChIKey
IZEKFCXSFNUWAM-UHFFFAOYSA-N
SMILES
C1(N(CCO)CCO)=NC(N2CCCCC2)=C2N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=N1
NCI Dictionary of Cancer Terms
dipyridamole
FDA UNII
64 ALC7F90C · 64ALC7F90C
NCI Drug Dictionary
dipyridamole
ATC code
1 AC07 · B01AC07
NIST Chemistry Reference
2 · Pyrimidine, 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-(58-32-2)
Comptox DTXSID
6040668 · DTXSID6040668
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Protein binding
97 · 97-99%
Excreted unchanged in urine
1 · 1-5%
Volume of distribution
1.33 · 1.33-3.53(L/kg)
Biological half-life
9 · 9-12 / Unch
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319-H335
Precautionary statements
261 · P261-P264-P271-P280-P302+P352-P305+P351+P338
PPE
95 · dust mask type N95 (US), Eyeshields, Gloves
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
WGK Germany
2 · 2
RTECS
7450000 · KK7450000
HS Code
2933599090 · 2933599090
Storage Class
11 · 11 - Combustible Solids
Toxicity
50 in · LD50 in rats: 8.4 g/kg orally; 208 mg/kg i.v. (Takenaka)
· 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Dipyridamole

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Dipyridamole

7.0

29.6

The recommended dose is 75 mg to 100 mg four times daily as an adjunct to the usual warfarin therapy. There are no non-adjunct labels.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 300 mg/day, Lowest Therapeutic Dose (LTD): 3.8 mg/kg-day, and Screening Dose: 0.001 mg/kg-day.

15-Dec-21

Safety data

PPE
dust mask type N95 (US), Eyeshields, Gloves
wgk
2
rtecs
KK7450000
hs_code
2933599090
Toxicity
LD50 in rats: 8.4 g/kg orally; 208 mg/kg i.v. (Takenaka)
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
26-36
Storage Class
11 - Combustible Solids
Hazard statements
H315-H319-H335
Precautionary statements
P261-P264-P271-P280-P302+P352-P305+P351+P338

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 4 items

70%

Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.

1 to 2.5 L/kg

2.3-3.5 mL/min/kg

Cellular LocationsCytoplasm
Metabolite PathwaysDipyridamole (Antiplatelet) Action Pathway

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >10000
Use ClassificationPharmaceuticals
Applications · 6 items

DescriptionDipyridamole (58-32-2) is a phosphodiesterase inhibitor (IC50=0.37, 0.38, 0.45, 0.9 and 4.5 μM for PDE11, 6, 10, 5 and 8 respectively.1,2 Potent equilibrative nucleoside transporter 1 (ENT1) inhibitor Ki=8.2 nM vs. 144.8 nM for ENT1 and ENT2 respectively.3 Antiplatelet activity.4

UsesSelective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation

UsesA phosphodiester, cGMP, and non-specific nucleoside transport inhibitor

UsesDipiridamol is known as a coronary vasodilating agent, although it also possesses specific antiaggregant activity. It is used for preventing thrombo-formation after cardiac valve replacement in combination with warfarin.

UsesDipyridamole prevents platelets sticking to the replacement heart valve and causing a blood clot on the valve. It is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease. This compound has been shown to suppress high glucose-induced osteopontin mRNA expression and protein secretion, as well as inhibit cAMP and cGMP hydrolysis. Research indicates that Dipyridamole is a non-specific nucleoside transport inhibitor with the ability to increase the effects of adenosine in sinoatrial and atrioventricular nodes. Dipyridamole is an inhibitor of ENT1 and ENT2.

General DescriptionDipyridamole, 2,2',2',2'''-[(4,8-di-1piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetrakisethanol (Persantine), may be used for coronary andmyocardial insufficiency. Its biggest use today, however, isas an antithrombotic in patients with prosthetic heart valves.It is a bitter, yellow, crystalline powder, soluble in diluteacids, methanol, or chloroform. A formulation containingdipyridamole and aspirin (Aggrenox) is currently beingmarketed as an antithromobotic.Dipyridamole is a long-acting vasodilator. Its vasodilatingaction is selective for the coronary system; it is indicatedfor long-term therapy of chronic angina pectoris. Thedrug also inhibits adenosine deaminase in erythrocytesand interferes with the uptake of the vasodilator adenosineby erythrocytes. These actions potentiate the effect ofprostacyclin (PGI2), which acts as an inhibitor to plateletaggregation.

Upstream & downstream products

Upstream raw materials

5-Aminoorotic acidNitric acidHydrogenPotassium cyanateDiethanolaminePhosphorus oxychloridePiperidineEthyl acetoacetatePhosphorus oxitrichloride2,6-Dichloro-4,8-dipiperidinopyrimidino[5,4-d]pyrimidine
Additional notes · 1 item

DefinitionChEBI: A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.